June 20, 2024

177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The aim of this study was to assess the association among toxicity, dosimetry of organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with 177 Lu-DOTATATE.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Mileva et al. (Thu,) studied this question.

synapsesocial.com/papers/68e63f56b6db6435875d088e https://doi.org/https://doi.org/10.1097/rlu.0000000000005330

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A review on lymphocyte radiosensitivity and its impact on radiotherapy2023 · 118 citations
2Guidelines for the measurement of glomerular filtration rate using plasma sampling2004 · 304 citations
3Safety of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease2022 · 20 citations
4A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours2018 · 65 citations
5Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume2016 · 46 citations

Preguntar a la IA

Me gusta

Guardar